Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.

Turkish journal of medical sciences - 1 Feb 2022

Şahin Ezgi, Yönal-Hindilerden İpek, Hindilerden Fehmi, Aday Aynur, Nalçacı Meliha

Abstract excerpt

BACKGROUND: JAK2V617F mutation is expressed in almost all polycthemia vera (PV), 55% of essential thrombocythemia (ET), and 65% of primary myelofibrosis (PMF) patients. Studies investigating phenotypic effects of JAK2V617F mutation on Philadelphianegative myeloproliferative neoplasms (Ph-negative MPNs) have reported controversial results. This study aims to determine the impact of JAK2V617F mutation on clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Myeloproliferative Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Open in PubMed Open full text

Identifiers

PMID: 34482679
DOI: 10.3906/sag-2103-247
PMCID: PMC10734827

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.PMID 34482679Read ↗

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.Semantic proximity Read ↗

Clinical implications of JAK2 mutations in myeloproliferative disorders.Semantic proximity Read ↗

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging DataSemantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

JAK2 V617F Mutational Burden and Clinical Findings Relationship in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.Semantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.